TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02761291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
Study: NCT03660631

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CVRS Intervention
Description: 1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVRS Intervention
Description: 1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider
Study: NCT00364130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low magnitude mechanical stimulus
Description: 10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (inactive) low magnitude mechanical stimulus
Description: 10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
Study: NCT00813033

Intervention type: OTHER
Group type: OTHER
Intervention: patient decision aid for endoscopy
Description: patient decision aid will be administered at the point of decision making
Study: NCT03385161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Study: NCT00440778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: 100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
Study: NCT01482351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP adherence intervention
Description: Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention control intervention
Description: This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
Study: NCT00055471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 10 mg
Description: 1 x 10 mg oral tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 15 mg
Description: 1 x 10 mg + 2 x 2.5 mg oral tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 22.5 mg
Description: 2 x 10 mg + 2 x 2.5 mg oral tablets once daily
Study: NCT00295971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT04623385

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone
Description: 1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: The standard therapy
Description: infected patients will receive the standard therapy for COVID-19 for 14 days
Study: NCT05425589

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adjustable strabismus surgery
Description: Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
Study: NCT03131453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520 50mg
Description: 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520 15mg
Description: 15 mg capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo for 15 and 50 mg capsules
Study: NCT01278160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
Study: NCT03442283

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin mineral supplementation
Description: supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
Study: NCT04041739

Intervention type: DIAGNOSTIC_TEST
Intervention: fungal osteomyelitis culture and sensitivity
Description: swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
Study: NCT04570267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL324
Description: Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL324
Description: Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of CSL324 formulation buffer for injection
Study: NCT02149615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinal nerve fibre layer measurement
Description: Measurement of retinal nerve fibre layer thickness using optic coherence tomography.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retinal nerve fibre layer measurement
Description: Measurement of retinal nerve fibre layer thickness using optic coherence tomography.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinal nerve fibre layer measurement
Description: Measurement of retinal nerve fibre layer thickness using optic coherence tomography.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinal nerve fibre layer measurement
Description: Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
Study: NCT03098628

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV Vaccine
Description: PCV vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV Vaccine
Description: PCV vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV Vaccine
Description: PCV vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV Vaccine
Description: PCV vaccination

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV Vaccine
Description: PCV vaccination
Study: NCT03091660

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Solution
Description: Given intravesically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Tokyo-172 Strain Solution
Description: Given intravesically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Tokyo-172 Strain Solution
Description: Given intravesically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Tokyo-172 Strain Vaccine
Description: Given ID

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04147585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Reduced Calorie Diet (IRCD)
Description: Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
Study: NCT01173536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Oral single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Oral single dose
Study: NCT04120337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid device + lidocaine patch
Description: The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique + lidocaine injection
Description: Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid device + lidocaine injection
Description: The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
Study: NCT03829683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Description: 50mL intravenously every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: 50mL intravenously every 6 hours
Study: NCT00606099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
Study: NCT01173536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral repeating dose
Study: NCT00606099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir dipivoxil
Description: Active Comparator
Study: NCT01248468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin, acetaminophen and caffeine
Description: 2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 100 mg Sumatriptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04275869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
Study: NCT03008343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation
Description: One kind of electric ablation machine from Angiodynamic company (USA)
Study: NCT04546243

Intervention type: PROCEDURE
Intervention: resection group
Description: patients received VATS

Intervention type: RADIATION
Intervention: radiotherapy group
Description: patients received radiotherapy
Study: NCT01992081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated telehealth system
Description: The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
Study: NCT03801109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric group
Description: Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic group
Description: There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical group
Description: A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline group
Description: This group will be the control group that did not take any action, perform the activities of daily life
Study: NCT03419624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg [Bydureon]
Description: Exenatide 2 mg injection once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 mg [Bydureon]
Description: Exenatide 2 mg injection once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection once weekly
Study: NCT03008343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: One kind of electric ablation machine from Angiodynamic company (USA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT00616161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: 0.5 microgram/kg/min IV for 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: 1.0 microgram/kg/min IV for 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: 1.5 microgram/kg/min IV for 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00445692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given Orally (PO)
Study: NCT04314661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
Description: After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
Description: After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
Description: Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
Description: Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
Study: NCT02376933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of metastatic lesions to the spine.
Study: NCT02663258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT03860077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content Cigarettes
Description: Very Low Nicotine Content Cigarettes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Content Cigarettes
Description: Normal Nicotine Content Cigarettes
Study: NCT01786343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily for either 5 or 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily for either 5 or 10 days.
Study: NCT04248075

Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.

Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.

Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.

Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
Study: NCT03530020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monolithic zirconia crowns
Description: full anatomical monolithic crowns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium silicate crowns
Description: lithium silicate glass ceramics are highly resistance to chipping
Study: NCT03186807

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonographic scan of fetal brain
Description: 1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures.